Search Result

Results for "

SHR

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) Amino Acid Derivatives (1) Androgen Receptor (1) Angiotensin Receptor (2) Apoptosis (7) Calcium Channel (2) CDK (3) EGFR (2) ERK (2) Guanylate Cyclase (1) HBV (1) Indoleamine 2,3-Dioxygenase (IDO) (1) JAK (2) mAChR (1) NF-κB (2) Oxytocin Receptor (1) p38 MAPK (2) PARP (1) PD-1/PD-L1 (3) PDGFR (2) Raf (1) Reactive Oxygen Species (2) ROR (1) Ser/Thr Protease (1) SGLT (1) TGF-β Receptor (1) Thrombopoietin Receptor (1) URAT1 (1) VEGFR (2)
By Research Areas:	Cancer (19) Cardiovascular Disease (9) Endocrinology (1) Infection (1) Inflammation/Immunology (4) Metabolic Disease (3) Neurological Disease (5)

By Targets:

Adrenergic Receptor (1)

Amino Acid Derivatives (1)

Androgen Receptor (1)

Angiotensin Receptor (2)

Apoptosis (7)

Calcium Channel (2)

CDK (3)

EGFR (2)

ERK (2)

Guanylate Cyclase (1)

HBV (1)

Indoleamine 2,3-Dioxygenase (IDO) (1)

JAK (2)

mAChR (1)

NF-κB (2)

Oxytocin Receptor (1)

p38 MAPK (2)

PARP (1)

PD-1/PD-L1 (3)

PDGFR (2)

Raf (1)

Reactive Oxygen Species (2)

ROR (1)

Ser/Thr Protease (1)

SGLT (1)

TGF-β Receptor (1)

Thrombopoietin Receptor (1)

URAT1 (1)

VEGFR (2)

By Research Areas:

Cancer (19)

Cardiovascular Disease (9)

Endocrinology (1)

Infection (1)

Inflammation/Immunology (4)

Metabolic Disease (3)

Neurological Disease (5)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-151367

SHR2415	ERK	Cancer
SHR2415 is a highly potent, selective and orally active ERK1/2 inhibitor. SHR2415 has inhibition activity for ERK1 and ERK2 with IC₅₀ values of 2.8 nM and 5.9 nM, respectively. SHR2415 exhibits high potency with an IC₅₀ value of 44.6 nM in Colo205 cells. SHR2415 can be used for the research of cancer .

HY-137448

Rezvilutamide

SHR3680
Androgen Receptor Cancer

Rezvilutamide (SHR3680) is an androgen receptor antagonist. Rezvilutamide (SHR3680) is used for the study of prostate cancer .

Rezvilutamide SHR3680	Androgen Receptor	Cancer
Rezvilutamide (SHR3680) is an androgen receptor antagonist. Rezvilutamide (SHR3680) is used for the study of prostate cancer .

HY-104065

Pyrotinib Maximum Cited Publications 12 Publications Verification SHR-1258	EGFR	Cancer
Pyrotinib (SHR-1258) is a potent and selective EGFR/HER2 dual inhibitor with IC₅₀s of 13 and 38 nM, respectively .

HY-144319

SHR5133

HBV Infection

SHR5133 is a highly potent, orally active HBV capsid assembly modulator. SHR5133 displays HBV DNA reduction (EC₅₀=26.6 nM) .
HY-P99944

SHR-1701

Retlirafusp alfa
PD-1/PD-L1 TGF-β Receptor Cancer

SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting PD-L1 and TGF-β for cancer research .

SHR5133	HBV	Infection
SHR5133 is a highly potent, orally active HBV capsid assembly modulator. SHR5133 displays HBV DNA reduction (EC₅₀=26.6 nM) .

SHR-1701 Retlirafusp alfa	PD-1/PD-L1 TGF-β Receptor	Cancer
SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting PD-L1 and TGF-β for cancer research .

HY-144269

SHR902275	Raf	Cancer
SHR902275 is a potent, selective, and orally active RAF inhibitor targeting RAS mutant cancers. SHR902275 has IC₅₀s of 1.6 nM, 10 nM, and 5.7 nM for cRAF, bRAF ^wt, and bRAF ^V600E, respectively. SHR902275 shows cell growth inhibition with GI₅₀s of 1.5 and 0.17 nM, 0.4 nM and 0.32 nM for H358, A375, Calu6, and SK-MEL2 cells respectively .

HY-104065B

Pyrotinib dimaleate Maximum Cited Publications 12 Publications Verification SHR-1258 dimaleate	EGFR	Cancer
Pyrotinib dimaleate (SHR-1258 dimaleate) is a potent and selective EGFR/HER2 dual inhibitor with IC₅₀s of 13 and 38 nM, respectively .

HY-155787

SHR5428	CDK	Cancer
SHR5428 is a potent, orally active, selective and noncovalent inhibitor of CDK7 with highly potent CDK7 enzymatic activity (IC₅₀=2.3 nM). SHR5428 inhibits triple negative breast cancer cellular activity on MDA-MB-468 cell (IC₅₀=6.6 nM) .

HY-128351

SHR1653	Oxytocin Receptor	Neurological Disease Endocrinology
SHR1653 is a highly potent, selective and brain penetrated oxytocin receptor (OTR) antagonist, with an IC₅₀ of 15 nM for hOTR .

HY-115879

SHR168442

ROR Inflammation/Immunology Cancer

SHR168442 is a modulator of retinoid-related orphan receptor gamma (RORγ) with an IC₅₀ value of 0.035 μM.

SHR168442	ROR	Inflammation/Immunology Cancer
SHR168442 is a modulator of retinoid-related orphan receptor gamma (RORγ) with an IC₅₀ value of 0.035 μM.

HY-114338

Dalpiciclib SHR-6390	CDK	Cancer
Dalpiciclib (SHR-6390) is an orally active and highly selective inhibitor of CDK4 and 6 with IC₅₀ values of 12.4 nM and 9.9 nM, respectively . Dalpiciclib shows antitumor activity against breast cancer and esophageal squamous cell carcinoma .

HY-114338A

Dalpiciclib hydrochloride SHR-6390 hydrochloride	CDK	Cancer
Dalpiciclib (SHR-6390) hydrochloride is an orally active and highly selective inhibitor of CDK4 and 6 with IC₅₀ values of 12.4 nM and 9.9 nM, respectively . Dalpiciclib hydrochloride shows antitumor activity against breast cancer and esophageal squamous cell carcinoma .

HY-P99422

Adebrelimab SHR-1316	PD-1/PD-L1 Apoptosis	Cancer
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) .

HY-P99822

Recaticimab SHR-1209	Ser/Thr Protease	Metabolic Disease
Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Receticimab mediates the degradation of PCSK9 by binding to PCSK9, increasing the level of low-density lipoprotein (LDL) receptors on the surface of hepatocytes, reducing the level of LDL in plasma, and achieving the goal of lowering blood lipids. Recaticimab has potential application in hypercholesterolemia .

HY-P9971

Camrelizumab 1 Publications Verification SHR-1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .

HY-123011

Henagliflozin SHR3824	SGLT	Metabolic Disease
Henagliflozin (SHR3824) is a potent selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with the IC₅₀ values of 2.38 and 4324 nM for human SGLT2 and SGLT1, respectively. Henagliflozin can be used in diabetes research .

HY-108713

Famitinib SHR1020	VEGFR PDGFR Apoptosis	Cancer
Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC₅₀ values of 2.3 nM, 4.7 nM and 6.6 nM, respectively . Famitinib exerts powerful antitumor activity in human gastric cancer cells and xenografts. Famitinib triggers apoptosis .

HY-112724

Ivarmacitinib SHR0302	JAK Apoptosis	Inflammation/Immunology Cancer
Ivarmacitinib (SHR0302) is a potent and orally active all members of the JAK family inhibitor, particularly JAK1. The selectivity of Ivarmacitinib for JAK1 is >10-fold for JAK2, 77-fold for JAK3, 420-fold for Tyk2. Ivarmacitinib inhibits JAK1-STAT3 phosphorylation and induces the apoptosis of hepatic stellate cells. Ivarmacitinib has anti-proliferative and anti-inflammatory effects .

HY-108713A

Famitinib malate SHR1020 malate	VEGFR PDGFR Apoptosis	Cancer
Famitinib (SHR1020) malate, an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC₅₀ values of 2.3 nM, 4.7 nM and 6.6 nM, respectively. Famitinib malate induces cell apoptosis. Famitinib malate exerts powerful antitumor activity in human gastric cancer cells and xenografts, it can be used for the research of cancer .

HY-114778

Fluzoparib 1 Publications Verification SHR3162; Fuzuloparib	PARP	Cancer
Fluzoparib (SHR3162) is a potent and orally active PARP1 inhibitor (IC₅₀=1.46±0.72 nM, a cell‐free enzymatic assay) with superior antitumor activity. Fluzoparib selectively inhibits the proliferation of homologous recombination repair (HR)‐deficient cells, and sensitizes both HR‐deficient and HR‐proficient cells to cytotoxic agents. Fluzoparib exhibits good pharmacokinetic properties in vivo and can be used for BRCA1/2-mutant relapsed ovarian cancer research .

HY-112724A

Ivarmacitinib sulfate SHR0302 sulfate	JAK Apoptosis	Inflammation/Immunology Cancer
Ivarmacitinib (SHR0302) sulfate is a potent and orally active all members of the JAK family inhibitor, particularly JAK1. The selectivity of Ivarmacitinib for JAK1 is >10-fold for JAK2, 77-fold for JAK3, 420-fold for Tyk2. Ivarmacitinib inhibits JAK1-STAT3 phosphorylation and induces the apoptosis of hepatic stellate cells. Ivarmacitinib has anti-proliferative and anti-inflammatory effects .

HY-145589

Rafutrombopag

SHR-8735
Thrombopoietin Receptor Cardiovascular Disease

Rafutrombopag is a thrombopoietin (TPO) agonist extracted from patent CN113929668 A.

Rafutrombopag SHR-8735	Thrombopoietin Receptor	Cardiovascular Disease
Rafutrombopag is a thrombopoietin (TPO) agonist extracted from patent CN113929668 A.

HY-W052011

Ruzinurad HR011303; SHR4640	URAT1	Metabolic Disease
Ruzinurad (HR011303) is a highly selective URATl inhibitor (WO2020088641, compound I). Ruzinurad can be used in the study of hyperuricemia .

HY-W143531

Perfluorohexyloctane NOV03; SHR8058	Others	Inflammation/Immunology
Perfluorohexyloctane (NOV03), a semifluorinated alkane, reduces tear film instability in Meibomian gland dysfunction and evaporative dry eye disease. Perfluorohexyloctane is a long-term tamponade agent. Perfluorohexyloctane increases tear film breakup time and lipid layer thickness .

HY-104065A

(Rac)-Pyrotinib

(Rac)-SHR-1258
Others Cancer

(Rac)-Pyrotinib ((Rac)-SHR-1258) is the racemate of Pyrotinib (HY-104065). Pyrotinib is a potent and selective EGFR/HER2 dual inhibitor.

(Rac)-Pyrotinib (Rac)-SHR-1258	Others	Cancer
(Rac)-Pyrotinib ((Rac)-SHR-1258) is the racemate of Pyrotinib (HY-104065). Pyrotinib is a potent and selective EGFR/HER2 dual inhibitor.

HY-128355A

(R)-IDO/TDO-IN-1	Indoleamine 2,3-Dioxygenase (IDO)	Others
(R)-IDO/TDO-IN-1 (compound 25) is an indoleamine-2,3-dioxygenase (IDO) inhibitor, with good pharmacokinetic properties. (R)-IDO/TDO-IN-1 exhibits anti-tumor activity in MC38 xenograft model. (R)-IDO/TDO-IN-1 shows synergistic effect with anti-PD-1 monoclonal antibody (SHR-1210) .

HY-155042

Antihypertensive agent 3	Angiotensin Receptor	Cardiovascular Disease
Antihypertensive agent 3 (compound 4a) is an antagonis of angiotensin II receptor 1. Antihypertensive agent 3 exhibits antihypertensive activity in a spontaneously hypertensive rats (SHRs) model .

HY-B1388

Homatropine methylbromide Homatropine methobromide	mAChR	Neurological Disease
Homatropine methylbromide (Homatropine methobromide) is muscarinic AChR antagonist, inhibits endothelial and smooth muscle muscarinic receptors of WKY-E and SHR-E with IC₅₀ of 162.5 nM and 170.3 nM, respectively.

HY-153350

ERK-IN-7

ERK Cancer

ERK-IN-7 (Example 10), an analogue of SHR2415 (HY-151367), is a potent ERK inhibitor with IC₅₀ of 5 nM and 7 nM against ERK1 and ERK2, respectively .

ERK-IN-7	ERK	Cancer
ERK-IN-7 (Example 10), an analogue of SHR2415 (HY-151367), is a potent ERK inhibitor with IC₅₀ of 5 nM and 7 nM against ERK1 and ERK2, respectively .

HY-107398

1-(2,3-Dichlorophenyl)ethanamine hydrochloride	Others	Cardiovascular Disease
1-(2,3-Dichlorophenyl)ethanamine hydrochloride is a phenylethanolamine N-methyltransferase (PNMT) inhibitor. 1-(2,3-Dichlorophenyl)ethanamine hydrochloride effectively reduces blood pressure of spontaneously hypertensive. 1-(2,3-Dichlorophenyl)ethanamine hydrochloride can be used for the research of blood pressure .

HY-P4296

H-Gly-Sar-Sar-OH	Amino Acid Derivatives	Others
H-Gly-Sar-Sar-OH is an orally active tripeptide. H-Gly-Sar-Sar-OH is transported through PepT1 within Caco-2 cells. H-Gly Sar Sar OH has potential applications in material transportation .

HY-106720

Amosulalol YM 09538	Adrenergic Receptor	Cardiovascular Disease
Amosulalol (YM 09538) is an orally active and dual inhibitor of α1/β1-Adrenergic Receptor. Amosulalol exhibits antihypertensive activity via α1-Adrenergic Receptor inhibition. Amosulalol decreases reflexogenic increases in heart rate and plasma renin activity (PRA) via β1-Adrenergic Receptor inhibition in spontaneously hypertensive rats (SHR) .

HY-N9113

1,3,5,6-Tetrahydroxyxanthone	Others	Cardiovascular Disease
1,3,5,6-Tetrahydroxyxanthone is a natural xanthone that can be isolated from Garcinia achachairu Rusby (Clusiaceae) branches. 1,3,5,6-Tetrahydroxyxanthone induces diuresis and saluresis in normotensive and hypertensive rats .

HY-153369

BAY-747	Guanylate Cyclase	Cardiovascular Disease Neurological Disease
BAY-747 is an orally active and brain-penetrant stimulator of soluble guanylate cyclase (sGC). BAY-747 reverses L-NAME induced memory impairments and enhances cognition of rats in the object location task (OLT). BAY-747 also decreases blood pressure in both conscious normotensive and spontaneously hypertensive rats (SHR). BAY-747 improves function of the skeletal muscle associated with Duchenne muscular dystrophy (DMD) in mdx/mTRG2 mice model .

HY-B0612

Lercanidipine 1 Publications Verification	Calcium Channel Apoptosis Reactive Oxygen Species p38 MAPK NF-κB	Cardiovascular Disease Neurological Disease
Lercanidipine is a third-generation, lipophilic, brain-penetrant, vascular-selective and orally active dihydropyridine-calcium channel blocker with a pIC₅₀ of 7.74 (converts from μM). Lercanidipine has long lasting antihypertensive action as well as reno- and neuro-protective effect. Lercanidipine also shows anti-oxidant, anti-inflammatory and anti-apoptotic properties. Lercanidipine can be used in cardiovascular and neurological research .

HY-B0612A

Lercanidipine hydrochloride 1 Publications Verification	Calcium Channel Apoptosis Reactive Oxygen Species p38 MAPK NF-κB	Cardiovascular Disease Neurological Disease
Lercanidipine is a third-generation, lipophilic, brain-penetrant, vascular-selective and orally active dihydropyridine-calcium channel blocker with a pIC₅₀ of 7.74 (converts from μM). Lercanidipine has long lasting antihypertensive action as well as reno- and neuro-protective effect. Lercanidipine also shows anti-oxidant, anti-inflammatory and anti-apoptotic properties. Lercanidipine can be used in cardiovascular and neurological research .

HY-103247

EMD 66684	Angiotensin Receptor	Cardiovascular Disease
EMD 66684 is an antagonist of Angiotensin II Type 1 (AT1) receptor. EMD 66684 shows potent binding affinities for the AT1 subtype Ang II receptor with an IC₅₀ value of 0.7 nM. EMD 66684 also serves as an antiischemic cytoprotectant ^- .

H-Gly-Sar-Sar-OH	Amino Acid Derivatives	Others
H-Gly-Sar-Sar-OH is an orally active tripeptide. H-Gly-Sar-Sar-OH is transported through PepT1 within Caco-2 cells. H-Gly Sar Sar OH has potential applications in material transportation .

Adebrelimab SHR-1316	PD-1/PD-L1 Apoptosis	Cancer
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) .

Recaticimab SHR-1209	Ser/Thr Protease	Metabolic Disease
Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Receticimab mediates the degradation of PCSK9 by binding to PCSK9, increasing the level of low-density lipoprotein (LDL) receptors on the surface of hepatocytes, reducing the level of LDL in plasma, and achieving the goal of lowering blood lipids. Recaticimab has potential application in hypercholesterolemia .

Camrelizumab 1 Publications Verification SHR-1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .

SHR-1701 Retlirafusp alfa	PD-1/PD-L1 TGF-β Receptor	Cancer
SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting PD-L1 and TGF-β for cancer research .

1,3,5,6-Tetrahydroxyxanthone	Flavonoids Source classification Guttiferae Hyperlcurn perforatum L. Plants Other Flavonoids	Others
1,3,5,6-Tetrahydroxyxanthone is a natural xanthone that can be isolated from Garcinia achachairu Rusby (Clusiaceae) branches. 1,3,5,6-Tetrahydroxyxanthone induces diuresis and saluresis in normotensive and hypertensive rats .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks